EGFR and melanoma: The therapeutic efficacy of PIT has been demonstrated in multiple pre-clinical animal models of human cancers including breast (HER2), pancreatic (carcinoembryonic antigen), bladder (EGFR), prostate (prostate-specific membrane antigen), glioblastoma (mesothelin and EGFR), and melanoma (EGFR) [17,37,39,41,259,260,261,262,263].